All News
Comorbidity Drives Risk of Death in Gout Patients
A study of men with gout from the US Veteran’s Health Administration (VHA) shows that excess mortality in gout could be attributed to comorbidities.
Read Article
SLE Higher Risk of Postoperative Cardiac Events
ACR Open Rheumatology reports that systemic lupus erythematosus (SLE) patients have a higher risk of postoperative major adverse cardiac events (MACE) that can be identified by common cardiac risk measures.
Read Article
Poor Outcomes in Lupus Patients Not at Target
A prospective, longitudinal systemic lupus erythematosus (SLE) cohort study examined outcomes and showed that failure to control SLE was common and associated with poorer outcomes including organ damage, glucocorticoid exposure, poor quality of life, and increased mortality.
Read Article
Effect of Intraarticular Steroid Shots on Knee OA Outcomes
In patients with osteoarthritis (OA) of the knee, intra-articular injections of steroids did not increase rates of either disease progression or subsequent knee replacement surgery, researchers said.
Read Article
Are Shoulder Conditions Incited by Vaccination?
A retrospective cohort study from Kaiser Permanente Southern California intramuscular vaccination given between 2016 and 2017 shows a small but significant increase in shoulder conditions, reported as an adverse event (AE) following intramuscular vaccination in the deltoid muscle.
Read Article
Iberdomide in Systemic Lupus Erythematosus
The NEJM reports that systemic lupus erythematosus (SLE) patients treated with iberdomide, a cereblon modulator, was effective at yielding a significant SRI-4 clinical response after 24 weeks.
Read Article
Seropositivity Linked to Bronchiectasis in Rheumatoid Arthritis
Rheumatoid arthritis associated bronchiectasis (RA-BR) is uncommon, and is unrelated to interstitial lung disease (ILD), but like ILD, can substantially impact RA outcomes.
Read Article
Disappointment Behind Acute Gout Hospitalizations
Analysis of emergency department visits from two UK hospitals shows a high rate of hospitalization, and low use of urate-lowering therapies (ULT) and treat-to-target (T2T) management.
Read Article
Environmental Pollutants Ups Autoimmune Disease Risk
An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD).
Read Article
Individualized Therapy in Ankylosing Spondylitis
Whether patients with ankylosing spondylitis (AS) would improve substantially with tumor necrosis factor (TNF) inhibitor therapy was predicted with moderate to high accuracy based only on a standard lab test and two measures of disease activity, researchers reported from a modeling study.
Read Article
Low Dose IL-2 Efficacy in Rheumatoid Arthritis
A novel biologic intervention trial has shown that subcutaneous, intermittent therapy with low-dose interleukin-2 (Ld-IL2) is potentially effective and safe in rheumatoid arthritis (RA).
Read Article
Efficacy and Safety of Mavrilimumab in Giant Cell Arteritis
A phase II trial in patients with active giant cell arteritis shows that mavrilimumab, a monoclonal antibody against granulocyte-macrophage colony-stimulating factor [GM-CSF]) is capable of inducing clinical remission.
Read Article
Predicting Spondylitis in At-Risk Relatives
The risk of developing axial spondyloarthritis (axSpA) if you’re a first-degree relative (FDRs) of an ankylosing spondylitis (AS) patient has been deflined by a 35 year follow-up study showing that if you are a FDR of axSpA you may be at higher risk of acute anterior uveitis (AAU).
Read Article
Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib
Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.
Read Article
Could Anifrolumab Work in Lupus Nephritis?
Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.
Read Article
Kawasaki Disease Guideline from ACR and Vasculitis Foundation
The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of
Read Article
Combo MTX and Leflunomide in Psoriatic Arthritis
A recent study has shown that the combination of methotrexate (MTX) plus leflunomide (LEF) yields better disease control in psoriatic arthritis, but may not be as well tolerated as monotherapy with MTX.
Read Article
Baricitinib’s COVID-19 Efficacy in the RECOVERY Trial
Pre-print results of the RECOVERY Trial has shown that when baricitinib (BAR) is given to hospitalized severe COVID-19 patients, it results in significantly less mortality.
Read Article
Failed Osteoarthritis Pulse Ultrasound Study
A promising therapy aimed at halting and even reversing the pathology underlying osteoarthritis (OA) of the knee failed to show any benefit in a randomized trial.
Read Article
Tocilizumab Works Best in Non-Mechanical Ventilated COVID-19 Patients
JAMA has published a meta-analysis of 15 studies of hospitalized patients with COVID-19 treated with tocilizumab and corticosteroids, showing that a clinically meaningful mortality benefit from tocilizumab (and steroids) was best seen in those not requiring invasive mechanical ventilation (IMV).
Read Article
